Thursday, June 6, 2019

Lung Therapeutics Finds $36M

Austin-based Lung Therapeutics, a biopharmaceuticals company which develops drugs for treating orphan, pulmonary indications such as Idiopathic Pulmonary Fibrosis (IPF), said this week that it has raised $36M in a Series C funding round

The story you have requested is only available to paid members of the TEXASTECHPULSE web site. Stories newer than 15 days are restricted to paid members only. Please login in order to access this members-only content, or become a member.